Replies to post #438115 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

p values for Alzheimer's treatment with blarcamesine from the Phase 2a trial.

This analysis showed that the higher blarcamesine (ANAVEX2-73) mean concentration arm had improved therapeutic responses of 78% and 88% in adjusted MMSE and adjusted ADCS-ADL, respectively, relative to the low/medium arm at 148 weeks (P-values < .0008 and <.0001, respectively). In addition to time, APOE e4 status (P < .0001), and blarcamesine (ANAVEX2-73) mean concentration were significant predictors (Figure 2a and 2b and Supplementary Tables 4b, 4c). Additional significant variables in this model were SIGMAR1 p.Gln2Pro, COMT p.Leu146fs, and APOE4 e4 status interactions with time.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167374/

Good luck and GOD bless,